GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (HKSE:03933) » Definitions » Valuation Rank

United Laboratories International Holdings (HKSE:03933) Valuation Rank


View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


United Laboratories International Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Majority of the company's sales are generated in China, followed by Europe, India and other countries.
Executives
Heren Far East #4 Limited 2201 Interest of corporation controlled by you
Heren Far East Limited 2101 Beneficial owner
Iq Eq Services (hk) Limited 2201 Interest of corporation controlled by you